

Board of Governors of the Federal Reserve System, August 23, 1996.

Jennifer J. Johnson

Deputy Secretary of the Board

[FR Doc. 96-21949 Filed 8-27-96; 8:45 am]

BILLING CODE 6210-01-F

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 12, 1996.

A. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Bankers Bancorp of Oklahoma, Inc.*, Oklahoma City, Oklahoma; to engage *de novo* in a joint venture through its subsidiary, Bankers Bank Systems, Oklahoma City, Oklahoma, in data processing activities, pursuant to § 225.25(b)(7) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, August 23, 1996.

Jennifer J. Johnson

Deputy Secretary of the Board

[FR Doc. 96-21948 Filed 8-27-96; 8:45 am]

BILLING CODE 6210-01-F

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System

TIME AND DATE: 11:00 a.m., Tuesday, September 3, 1996.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:

Mr. Joseph R. Coyne, Assistant to the Board; (202) 452-3204. You may call (202) 452-3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: August 26, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96-22052 Filed 8-26-96; 10:59 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and the Advisory Commission on Childhood Vaccines (ACCV), Subcommittee on Vaccine Safety: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease

Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.-1:30 p.m., September 9, 1996. 8:30 a.m.-12:30 p.m., September 10, 1996.

Place: Hubert H. Humphrey Building, Room 702A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Purpose: The Committee shall advise and make recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters to be Discussed: The Committee will receive reports on the status of NVAC nominees to replace members whose terms have ended, status of new exofficio members from the Department of Agriculture and the Health Care Financing Administration, and a discussion regarding the addition of liaison representatives to the Committee; the recruitment status for the Director, National Vaccine Program Office (NVPO); update alternatives for adverse event surveillance and funding options; update immunization registry; confidentiality issues; NVAC endorsement of the immunization information system confidentiality paper; update philosophical exemption to immunization; the Measles Vaccine Timing Study—Discussion of Edmonston-Zagreb (EZ) Vaccine Study; Institutes of Medicine risk communication safety forum; an update on the Subcommittee on Immunization Coverage Draft Papers, Thirteen Points of Leverage to Increase Coverage and Access to Immunization; an update on the Subcommittee on Future Vaccines, vaccine research partnership, and a status report on Sabin case studies; an update on the Subcommittee on Vaccine Safety; update on Adult Immunization Work Group; report on children's vaccine initiative; update on the National Vaccine Injury Compensation Program, a report from the Task Force on Safer Vaccines, a review of adverse events litigation and compensation in adults; and an update on Acellular Pertussis.

Agenda items are subject to change as priorities dictate.

Name: NVAC Subcommittee on Vaccine Safety and the ACCV, Subcommittee on Vaccine Safety.

Time and Date: 1:30 p.m.-5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 425A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This joint ACCV/NVAC subcommittee will review issues relevant to

vaccine safety and adverse reactions to vaccines.

Matters to be Discussed: The Subcommittee will discuss the inclusion of influenza and pneumococcal vaccines in the National Vaccine Injury Compensation Program summation, direction and closure; focus of safety subcommittees; and a review of report and recommendations from the Task Force on Safer Childhood Vaccines.

Name: NVAC Subcommittee on Immunization Coverage.

Time and Date: 1:30 p.m.–5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters to be Discussed: The Subcommittee will discuss the forum on assessment and related immunization issues; the outline for the Subcommittee's report; and the assessment of immunization coverage.

Name: NVAC Subcommittee on Future Vaccines.

Time and Date: 1:30 p.m.–5 p.m., September 9, 1996.

Place: Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will develop policy options and guide the National Vaccine Program activities which will lead to development, licensure, and best use of new and existing vaccines in the simplest possible immunization schedules.

Matters to be Discussed: The Subcommittee will discuss updates on vaccine procurement strategies, the United States Agency for International Development vaccine research agenda, and a discussion of case studies in vaccine development.

Contact Person for More Information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639-7250.

This notice is being published less than 15 days prior to the meeting due to the inability to transmit the document electronically.

Dated: August 22, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-21924 Filed 8-27-96; 8:45 am]

BILLING CODE 4163-18-M

Health Resources and Services Administration

Advisory Council; Notice of Establishment

Pursuant to the Federal Advisory Committee Act, Public Law 92-463 (5 U.S.C. Appendix 2), the Secretary, Department of Health and Human Services announces the establishment of the following advisory council.

Designation: Advisory Committee to the Administrator, HRSA.

Purpose: Advises the Secretary of HHS and the Administrator of HRSA on policy matters pertinent to HRSA mission responsibilities in the conduct and support of health care delivery, health workforce, and related programs.

The committee may make recommendations concerning program development, resource allocation, and HRSA administrative practices and policies, and other specific matters which affect the operation of the Agency.

Structure: The Committee shall consist of the Secretary or designee as Chair and 16 members. Eleven members shall be authorities who are knowledgeable in the fields of health care delivery and finance, the health workforce and training of the workforce, public health, and the special needs of disadvantaged populations. Five members shall be representatives of the general public.

Dated: August 22, 1996.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 96-21919 Filed 8-27-96; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

Notice of Meeting of the National Advisory Council for Human Genome Research

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Advisory Council for Human Genome Research, National Center for Human Genome Research, September 16-17, 1996, Holiday Inn, Washington/Chevy Chase, Palladian West/Center, 5522 Wisconsin Avenue, Chevy Chase, Maryland.

This meeting will be open to the public on Monday, September 16, from 8:30 to 1:00 p.m. to discuss administrative details or other issues relating to committee activities. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on September 16 from 1:00 p.m. to recess and on September 17 from 8:30 a.m. to adjournment, for the

review, discussion and evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dr. Elke Jordan, Deputy Director, National Center for Human Genome Research, National Institutes of Health, Building 31, Room 4B09, Bethesda, Maryland 20892, (301) 496-0844, will furnish the meeting agenda, rosters of Committee members and consultants, and substantive program information upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Jane Ades, (301) 594-1229, two weeks in advance of the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.172, Human Genome Research)

Dated: August 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-21897 Filed 8-27-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meetings of the National Cancer Advisory Board and its Subcommittee

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Cancer Advisory Board, National Cancer Institute, and its Subcommittees on September 10-11, 1996. Except as noted below, the meetings of the Board and its Subcommittees will be open to the public to discuss issues relating to committee business as indicated in the notice. Attendance by the public will be limited to space available.

A portion of the Board meeting will be closed to the public in accordance with the provisions set forth in secs. 552b(c)(4), 552b(c)(6), and 552(c)(9)(B), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications and for discussion of issues pertaining to programmatic areas and/or NCI personnel, and discussion of subcommittee recommendations regarding NCI staff support to the Board and operating procedures. These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning the individuals associated